UK-US Drug Deal May Cause 229,000 Excess Deaths

An analysis indicates that the UK-US trade deal, agreed upon in December, could result in 229,000 excess deaths in England. This projection stems from the National Health Service (NHS) needing to allocate £45 billion from essential services to cover the costs of new medicines under the agreement.

Ministers have stated that the deal aims to protect British drug exports from US tariffs and provide patients in England with access to potentially life-extending medications that might otherwise be unavailable. The analysis, however, suggests a significant negative impact on public health outcomes.

The projected excess deaths are a consequence of the increased financial burden on the NHS, which may necessitate cuts to other vital services or a reduction in the availability of treatments. The £45 billion diversion of funds is expected to strain the healthcare system's capacity to provide comprehensive care.

This analysis highlights a potential trade-off between economic considerations for pharmaceutical exports and the direct health and mortality rates of the UK population. The findings raise concerns about the long-term implications of the trade agreement on the sustainability and effectiveness of the NHS.